Abstract | INTRODUCTION: METHODS AND RESULTS: Patients who had at least monthly occurrences of syncope and a positive tilt-table test were included in the study. A total of 61 patients were randomly allocated to treatment either with midodrine or with fluid, salt tablets, and counseling. Midodrine was given at a starting dose of 5 mg three times a day and increased up to a dose of 15 mg three times a day when required. Midodrine was given during the daytime every 6 hours. Thirty-one patients were assigned to treatment with midodrine; the other 30 patients were advised to increase their fluid intake and were instructed to recognize their prodromes and abort the progression to syncope. Patients were followed-up for at least 6 months. A quality-of-life questionnaire was administered at the time of randomization and 6 months after. At the 6-month follow-up, 25 (81%) of 31 midodrine-treated patients and 4 (13%) of the 30 fluid-therapy patients had remained asymptomatic (P < 0.001). One patient had to discontinue taking midodrine due to severe side effects and another six patients experienced minor side effects that did not require drug discontinuation. CONCLUSION:
Midodrine appeared to provide a significant benefit in patients with neurocardiogenic syncope. To prevent recurrence of symptoms, dose adjustments were required in about one third of patients.
|
Authors | A Perez-Lugones, R Schweikert, S Pavia, J Sra, M Akhtar, F Jaeger, G F Tomassoni, W Saliba, F M Leonelli, D Bash, S Beheiry, J Shewchik, P J Tchou, A Natale |
Journal | Journal of cardiovascular electrophysiology
(J Cardiovasc Electrophysiol)
Vol. 12
Issue 8
Pg. 935-8
(Aug 2001)
ISSN: 1045-3873 [Print] United States |
PMID | 11513446
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic alpha-Agonists
- Midodrine
|
Topics |
- Adrenergic alpha-Agonists
(therapeutic use)
- Adult
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Kentucky
- Male
- Middle Aged
- Midodrine
(therapeutic use)
- Prospective Studies
- Quality of Life
(psychology)
- Recurrence
- Severity of Illness Index
- Surveys and Questionnaires
- Syncope, Vasovagal
(drug therapy)
- Treatment Outcome
- Wisconsin
|